AI-Enhanced CT Platform for Radiation Oncologists Gets FDA Nod

The Food and Drug Administration (FDA) has granted 510(k) clearance for the artificial intelligence (AI)-enabled Elekta Evo CT-Linac system, which may facilitate improved visualization and targeted treatment in radiation oncology procedures.

Going beyond the use of conventional cone-beam computed tomography (CBCT), the Elekta Evo CT-Linac system reduces scatter and improves the quality of image reconstruction, according to Elekta, the manufacturer of the Elekta Evo CT-Linac platform.

Elekta said the system’s use of Iris® high-definition AI-enhanced CT imaging provides better clarity of critical structures and target areas, fostering enhanced precision in treatment.

"Iris provides enhanced image quality. The reduction in artifacts and improved soft tissue contrast not only enhance daily image guidance for precise patient positioning but also allows us to see anatomical changes with greater confidence. This capability maximizes targeting precision and truly personalizes care for each patient,” noted Eenas Omari, Ph.D., an associate professor of radiation oncology at the Medical College of Wisconsin in Milwaukee.